MX368484B - Levadura recombinante para usarse para producir una respuesta inmune humoral protectora contra antígenos definidos. - Google Patents

Levadura recombinante para usarse para producir una respuesta inmune humoral protectora contra antígenos definidos.

Info

Publication number
MX368484B
MX368484B MX2014007183A MX2014007183A MX368484B MX 368484 B MX368484 B MX 368484B MX 2014007183 A MX2014007183 A MX 2014007183A MX 2014007183 A MX2014007183 A MX 2014007183A MX 368484 B MX368484 B MX 368484B
Authority
MX
Mexico
Prior art keywords
immune response
response against
humoral immune
vaccination
producing
Prior art date
Application number
MX2014007183A
Other languages
English (en)
Spanish (es)
Other versions
MX2014007183A (es
Inventor
Breunig Karin
Behrens Sven-Erik
Original Assignee
Martin Luther Univ Halle Wittenberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47681476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX368484(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Martin Luther Univ Halle Wittenberg filed Critical Martin Luther Univ Halle Wittenberg
Publication of MX2014007183A publication Critical patent/MX2014007183A/es
Publication of MX368484B publication Critical patent/MX368484B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0002Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/10011Birnaviridae
    • C12N2720/10034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
MX2014007183A 2011-12-13 2012-12-12 Levadura recombinante para usarse para producir una respuesta inmune humoral protectora contra antígenos definidos. MX368484B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011121069A DE102011121069A1 (de) 2011-12-13 2011-12-13 Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene
PCT/DE2012/001205 WO2013107436A1 (de) 2011-12-13 2012-12-12 Vakzinierung mittels rekombinanter hefe durch erzeugung einer protektiven humoralen immunantwort gegen definierte antigene

Publications (2)

Publication Number Publication Date
MX2014007183A MX2014007183A (es) 2014-11-25
MX368484B true MX368484B (es) 2019-10-04

Family

ID=47681476

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014007183A MX368484B (es) 2011-12-13 2012-12-12 Levadura recombinante para usarse para producir una respuesta inmune humoral protectora contra antígenos definidos.

Country Status (15)

Country Link
US (1) US11065312B2 (enExample)
EP (1) EP2844759B1 (enExample)
JP (1) JP6313215B2 (enExample)
KR (1) KR102027400B1 (enExample)
CN (1) CN104428417B (enExample)
BR (1) BR112014014390B1 (enExample)
CA (1) CA2859231C (enExample)
DE (2) DE102011121069A1 (enExample)
DK (1) DK2844759T3 (enExample)
ES (1) ES2690792T3 (enExample)
MX (1) MX368484B (enExample)
PL (1) PL2844759T3 (enExample)
RU (1) RU2630620C2 (enExample)
WO (1) WO2013107436A1 (enExample)
ZA (1) ZA201405034B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017012109A1 (de) * 2017-12-27 2019-06-27 Martin-Luther-Universität Halle-Wittenberg Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis
CN109467606A (zh) * 2018-11-15 2019-03-15 大连理工大学 一种大肠杆菌肠毒素STa-LTB-STb融合蛋白及其编码基因和应用
JP7372647B2 (ja) * 2019-06-27 2023-11-01 国立研究開発法人農業・食品産業技術総合研究機構 α‐リノレン酸産生能が向上した酵母またはその培養物
CN110646614B (zh) * 2019-07-15 2023-05-23 新乡学院 Ibdv抗体的elisa试剂盒和测试方法、有效抗体效价确定方法
CN114870006A (zh) * 2022-04-13 2022-08-09 河北农业大学 一种etec疫苗及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0474676A4 (en) 1989-05-30 1993-02-24 The Commonwealth Scientific And Industrial Research Organization Production of ibdv vp2 in highly immunogenic form
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US6234977B1 (en) 2000-01-28 2001-05-22 Michael Christy Variable-force monofilament sensory device and methods of using same
WO2002039951A2 (en) 2000-11-15 2002-05-23 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
CN100381565C (zh) * 2003-03-24 2008-04-16 英特威国际有限公司 表达典型和变异ibdv株系特异性的病毒中和表位的传染性法氏囊病病毒(ibdv)突变株
ES2242542B1 (es) * 2004-04-30 2006-12-16 Consejo Superior De Investigaciones Cientificas Procedimiento para la produccion en levaduras de capsidas virales vacias compuestas por proteinas derivadas de pvp2 del virus causante de la enfermedad de la bursitis infecciosa (ibdv).
EP1784211A4 (en) * 2004-07-29 2010-06-30 Novartis Vaccines & Diagnostic IMMUNOGENIC COMPOSITIONS FOR GRAMPOSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE
EP2460533A3 (en) 2004-10-18 2014-01-08 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
KR101492524B1 (ko) 2006-02-02 2015-02-12 글로브이뮨 면역 반응 유도를 위한 효모-기반 백신
KR101001023B1 (ko) * 2007-06-12 2010-12-14 성균관대학교산학협력단 효모 표면 발현 시스템을 이용한 파스튜렐라증 치료 또는예방용 백신
DE102008057451A1 (de) 2008-11-14 2010-05-20 Martin-Luther-Universität Halle-Wittenberg Verfahren zur oralen Vakzinierung mittels rekombinanter Hefen
CN101638824B (zh) 2009-03-16 2012-08-08 浙江双友物流器械股份有限公司 一种耐磨织带
JP5913103B2 (ja) 2009-09-14 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法

Also Published As

Publication number Publication date
WO2013107436A1 (de) 2013-07-25
DE112012005213A5 (de) 2014-11-13
US11065312B2 (en) 2021-07-20
RU2014127435A (ru) 2016-02-10
ES2690792T3 (es) 2018-11-22
EP2844759A1 (de) 2015-03-11
JP6313215B2 (ja) 2018-04-18
CN104428417A (zh) 2015-03-18
DE102011121069A1 (de) 2013-06-13
BR112014014390A2 (pt) 2020-12-08
PL2844759T3 (pl) 2019-01-31
BR112014014390B1 (pt) 2022-08-09
RU2630620C2 (ru) 2017-09-11
CA2859231C (en) 2019-04-30
KR20140105821A (ko) 2014-09-02
JP2015507472A (ja) 2015-03-12
ZA201405034B (en) 2015-12-23
CN104428417B (zh) 2020-05-05
US20150190486A1 (en) 2015-07-09
KR102027400B1 (ko) 2019-10-04
DK2844759T3 (en) 2018-11-05
EP2844759B1 (de) 2018-07-18
MX2014007183A (es) 2014-11-25
WO2013107436A8 (de) 2015-01-15
CA2859231A1 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
ZA201301013B (en) Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
MY186066A (en) Anti-phf-tau antibodies and their uses
IN2014CN02136A (enExample)
MY181688A (en) Improved production of fatty acid derivatives
WO2013054199A3 (en) Cmv antigens and uses thereof
WO2012149307A3 (en) Synthetic long peptide (slp)-based vaccines
NZ705606A (en) Methods for identifying antibodies with reduced immunogenicity
IN2015KN00323A (enExample)
MX346475B (es) Peptidos inmunogenicos monomericos y multimericos.
MX368484B (es) Levadura recombinante para usarse para producir una respuesta inmune humoral protectora contra antígenos definidos.
MX350096B (es) Preservación asistida con vacío de productos biológicos, en particular de vacunas.
SG10201808644PA (en) Recombinant mycobacterium as a vaccine
WO2012112416A3 (en) Method of producing n-butyraldehyde
IN2015DN03026A (enExample)
WO2013019603A3 (en) Linear expression cassettes and uses thereof
IN2014CN02963A (enExample)
EP2725098A4 (en) KLUYVEROMYCES LACTIS YEAST STRAIN AND PROCESS FOR OBTAINING SUGARS, ETHANOL AND BETA-GALACTOSIDASE AND BIOMASS
HK1202070A1 (zh) 用於肿瘤免疫疗法的疫苗
WO2011100508A3 (en) Methods and compositions related to glycoprotein-immunoglobulin fusions
NZ603431A (en) Parapoxvirus vectors containing rabies virus antigen
EA028913B9 (ru) Получение антител высокой чистоты в pichia pastoris
WO2015070207A3 (en) Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
MX374919B (es) ANTÍGENOS Y COMBINACIONES DE ANTÍGENOS PARA USARSE PARA ELEVAR LA RESPUESTA INMUNE CONTRA Haemophilus influenzae.
GB201120634D0 (en) Adjuvant polypeptide
RU2011115880A (ru) Способ получения селенсодержащего препарата биомассы laetiporus sulphureus mz-22

Legal Events

Date Code Title Description
FG Grant or registration